Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rentokil
RTO
|
+$514M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$210M |
| 3 |
TFI International
TFII
|
+$145M |
| 4 |
Ambev
ABEV
|
+$142M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$8.38B |
| 2 |
Apple
AAPL
|
+$5.7B |
| 3 |
Amazon
AMZN
|
+$3.72B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.64B |
| 5 |
Mastercard
MA
|
+$3.47B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.73% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
751
DELISTED
Avadel Pharmaceuticals
AVDL
| $8.63M | 0.01% |
+1,207,530
| New | +$8.47M |
|
752
Canadian National Railway
CNI
$76.9B
| $8.58M | 0.01% |
72,290
-195,980
| -73% | -$23.4M |
|
753
AST SpaceMobile
ASTS
$17.5B
| $8.54M | 0.01% |
1,772,351
-1,763,795
| -50% | -$10.6M |
|
754
Ecolab
ECL
$78.6B
| $8.42M | 0.01% |
57,838
-232
| -0.4% | -$34.1K |
|
755
Tyson Foods
TSN
$21.4B
| $8.35M | 0.01% |
134,136
-29,050
| -18% | -$1.89M |
|
756
Northrop Grumman
NOC
$76B
| $8.34M | 0.01% |
15,282
+5,837
| +62% | +$3.04M |
|
|
GTLS
757
DELISTED
Chart Industries
GTLS
| $8.27M | 0.01% |
71,725
+65,598
| +1,071% | +$10.5M |
|
758
Trip.com Group
TCOM
$29.3B
| $8.25M | 0.01% |
239,900
-239,900
| -50% | -$6.89M |
|
|
BLU
759
DELISTED
BELLUS Health Inc.
BLU
| $8.24M | 0.01% |
1,003,861
-559,985
| -36% | -$5.22M |
|
|
BDXB
760
DELISTED
Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6.00% Mandatory Convertible Preferred Stock, Series B
BDXB
| $8.23M | 0.01% |
165,200
-155,000
| -48% | -$7.48M |
|
761
Norfolk Southern
NSC
$75B
| $8.22M | 0.01% |
33,369
-25,085
| -43% | -$5.93M |
|
762
Amprius Technologies
AMPX
$1.34B
| $8.16M | 0.01% |
1,029,427
-1,003,231
| -49% | -$9.19M |
|
763
Xcel Energy
XEL
$48.8B
| $8.04M | 0.01% |
114,701
-80,965
| -41% | -$5.39M |
|
764
Cytokinetics
CYTK
$10.9B
| $7.97M | 0.01% |
173,930
+144,004
| +481% | +$6.2M |
|
765
Akamai
AKAM
$16.5B
| $7.94M | 0.01% |
94,133
+61,279
| +187% | +$5.33M |
|
766
Prudential Financial
PRU
$42.6B
| $7.92M | 0.01% |
79,649
-17,921
| -18% | -$1.81M |
|
767
PureCycle Technologies
PCT
$1.27B
| $7.91M | 0.01% |
1,169,588
-1,169,592
| -50% | -$8.43M |
|
768
Moderna
MRNA
$23B
| $7.86M | 0.01% |
43,795
-466,893
| -91% | -$76.3M |
|
|
TCVA
769
DELISTED
TCV Acquisition Corp. Class A Ordinary Shares
TCVA
| $7.83M | 0.01% |
780,252
-780,264
| -50% | -$7.74M |
|
770
Deutsche Bank
DB
$69.6B
| $7.8M | 0.01% |
688,257
-688,257
| -50% | -$6.79M |
|
|
CBAY
771
DELISTED
Cymabay Therapeutics
CBAY
| $7.79M | 0.01% |
+1,243,669
| New | +$4.73M |
|
772
Weatherford International
WFRD
$6.07B
| $7.7M | 0.01% |
151,232
+131,136
| +653% | +$5.4M |
|
773
Bio-Rad Laboratories Class A
BIO
$8.74B
| $7.61M | 0.01% |
18,092
-8,248
| -31% | -$3.33M |
|
774
Intel
INTC
$460B
| $7.61M | 0.01% |
287,815
-260,107
| -47% | -$7.22M |
|
775
Realty Income
O
$60.1B
| $7.58M | 0.01% |
119,569
-27,167
| -19% | -$1.69M |
|
Similar funds
Janus Henderson Group's Q4 2022 Portfolio in Review
As of Q4 2022, Janus Henderson Group held 2,666 positions worth $140B, down 48% from $267B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Janus Henderson Group withdrew a net $148B in Q4 2022, closing 210 positions and reducing 1,907 holdings. Its most notable exit was Terminix Global Holdings, Inc., an estimated $901M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Janus Henderson Group opened a new position in Rentokil worth $510M.
- Janus Henderson Group's largest Q4 2022 buy was Rentokil: 16,564,405 shares worth $510M.
- Janus Henderson Group added most to Apellis Pharmaceuticals in Q4 2022, an estimated $210M increase.
- Janus Henderson Group's biggest Q4 2022 reduction was Microsoft, cutting an estimated $8.38B.
- Janus Henderson Group fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $901M.
- Janus Henderson Group's ten largest holdings make up 22% of its $140B portfolio in Q4 2022.
- Janus Henderson Group opened 131 new positions and closed 210 in Q4 2022.
- Janus Henderson Group's portfolio value fell 48% quarter-over-quarter to $140B.
Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.